Keeping the lid sealed on Medical Science to ensure its translation into Medical Practice..Melanoma..Jim Breitfeller

“To keep the lid sealed on this corruption of medical science—and to ensure its translation into medical practice—there is a complex web of corporate influence that includes disempowered regulatory agencies, commercially sponsored medical education, brilliant advertising, expensive public relations campaigns, and manipulation of free media coverage. And last, but not least, are the financial ties between many of the most trusted medical experts and the medical industry. These relationships bear a remarkable resemblance to the conflicts of interest the Securities and Exchange Commission recently brought to a halt after learning that securities analysts were receiving bonuses for writing reports that drove up stock prices with the intent of bringing in more investment banking business.”


Quoted from:
Overdosed America by John Abramson MD, page 9

Source: http://www.olccme.com/managingmelanoma/

Is it one Big Infomercial? Commercial Support of this Educational Meeting?

Financial ties between many of the most trusted medical experts and the medical industry.

And Bristol Myer Squibb can’t open Compassionate Drug use to the Critically Ill Patients.

Who is watching the Hen House? What happen to the code of ethics?





Disclosure
DISCLOSURE STATEMENT AND RESOLUTION OF ANY CONFLICTS OF INTEREST
Not an official event of the ASCO Annual Meeting. Not sponsored or endorsed by ASCO or The ASCO Cancer Foundation.
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, all educational programs sponsored by the Oncology Learning Center (OLC) demonstrate fair balance, complete independence from any commercial supporters, objectivity, and scientific rigor. All faculty, authors, editors, OLC staff and planning committee members participating in an educational activity who are in control of content or in communication with faculty are required to disclose any relevant financial interest or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an OLC educational activity. All disclosures will be made available to all activity participants prior to the conduct of its educational activity. In addition, all conflicts of interest will be resolved prior to the conduct of its educational activity.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Oncology Learning Center does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Oncology Learning Center. Please refer to the official prescribing information for each product for discussion of approved indicated, contraindications, and warnings.

DISCLAIMER

Participants of OLC's educational activities have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development and practices. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
In a related Story
FBI: Syracuse man downloaded Bristol-Myers Squibb's process for making cutting-edge cancer drug
By Douglass Dowty / The Post-Standard
February 04, 2010, 5:47PM

"When you marry the devil's daughter don't be surprised when your father-in-law comes to visit."
~unknown~

Syracuse, NY -- Among the trade secrets a Syracuse man took from Bristol-Myers Squibb were steps to produce a multi-million dollar drug under development to treat a deadly form of cancer, FBI agents said.
Shalin Jhaveri, 29, was arrested Tuesday after a two-month investigation by the company and the FBI. He was living in an apartment on East Water Street in Hanover Square.
Jhaveri was in a management training program at Bristol’s East Syracuse facility, which develops cutting edge drugs known as biologics, federal authorities said. While there, he downloaded confidential procedures for biologics that he e-mailed to a potential business partner in his native India, prosecutors said.

Jhaveri’s ultimate goal was to start his own biopharmaceutical company, Cherish Bio Services, in India, according to court documents. His business partner was a potential investor who FBI agents recorded talking to Jhaveri on Jan. 25, court documents show.
During that conversation, Jhaveri told the partner he had set up a Gmail account and sent procedures for making “Anti-Human CD137 Monoclonal Antibody,” a biologics drug for patients with malignant melanoma. The rare skin cancer has no proven cure in its advanced stages.

Human CD137 (4-1BB) is expressed on activated T cells within 24-48 hours of activation.

That’s why the drug is a potential blockbuster for Bristol that could bring in $1 billion a year if it reaches mass production, said a stock analyst who monitors Bristol’s products. Right now, the drug is in early stages of clinical testing.

“It’s a big deal,” said Les Funtleyder, a health care strategist with Miller Tabak & Co. “If it were to succeed, it could be a blockbuster.”
He said biologics use animal cells to create pharmaceuticals, which cost a lot of money to produce and test. He estimated that Bristol could have spent up to $500 million developing this drug, BMS-663513, and others like it.

“It’s not easy to do,” he said. “It takes a lot of time and money.”
Bristol officials, who declined comment for this story, began tracking Jhaveri’s actions in December after finding documents on his work laptop that included an application to the government of India to start his own biopharmaceutical company, court records show. Computer specialists found Jhaveri had downloaded 45 gigabytes of information onto an external drive.

Soon afterward, authorities recorded a phone conversation Jhaveri had with the business partner from India. Their correspondence led to a meeting in Syracuse at the Renaissance Hotel on Tuesday, according to court documents.

There, Jhaveri showed the partner virtually all the “Standard Operating Procedure” documents kept at the East Syracuse facility, court records state. These included the trade secrets for the melanoma drug, among many others. All together, Jhaveri had 1,327 standard operating procedures, all of which were confidential, court records state.

An FBI agent confronted Jhaveri, who admitted to sending the confidential drug information and taking the standard operating procedures without authorization, court documents state.

Jhaveri, who holds a Ph.D. and was a former graduate research assistant at Cornell University, is currently in federal custody without bail. A detention hearing is scheduled for Monday in Syracuse.

Source:http://www.syracuse.com/news/index.ssf/2010/02/fbi_sryacuse_man_downloaded_st.htmlDisclosure

As you can see, Bristol Meyer Squibb is infiltrated with corruption.




Take Care,

Jimmy B